Ruxolitinib Phosphate

磷酸芦可替尼

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameRuxolitinib Phosphate
Drug Alias NameRuxolitinib芦可替尼磷酸盐ruxolitinibum卢索替尼磷酸盐磷酸鲁索替尼 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsChronic eosinophilic leukemia (CEL)Coronavirus Disease 2019 (COVID-19)Prurigo Nodularis +[77] 
Global Approved IndicationsPrimary Myelofibrosis
Approved Indications in ChinaPrimary Myelofibrosis
Original Approved Country/TerritoryUnited States
Original Approved Date2011/11/16
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstitutePeople'S Liberation Army Air Force Military Medical UniversityTiofarma Bv +[31] 
Inactive CompaniesUniversity Of California San FranciscoOhsu Knight Cancer InstituteTufts Medical Center Inc +[14] 
Active IndicationsChronic eosinophilic leukemia (CEL)Coronavirus Disease 2019 (COVID-19)Prurigo Nodularis +[52] 
Inactive IndicationsSolid tumoursCytokine Release SyndromePsoriasis +[25] 

Other Information

ATC CodeL01XE18
Related LinksWikipediaDrugBankKEGG